“The US Food and Drug Administration (FDA) has accepted for review Iroko Pharmaceuticals' new drug application (NDA) for SoluMatrix meloxicam, a low dose nonsteroidal anti-inflammatory drug (NSAID), for the proposed indication of management of osteoarthritis pain. The NDA is based on data from a m
1
Novartis exercises option with Conatus for NASH treatment - Pharmaceutical Business review
Pfizer, Merck start two Phase III clinical trials of avelumab to treat gastric cancers - Pharmaceutical Business review
FDA accepts to review Iroko NDA for SoluMatrix Meloxicam in osteoarthritis pain - Pharmaceutical Business review
Prosensa starts re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy - Pharmaceutical Business review
